ClinicalTrials.gg
RecruitingNCT06226194GENBASUUpdated Mar 6, 2024

Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery

An observational study in Bariatric Surgery Candidate, Obesity, Morbid and Genetic Predisposition, sponsored by Institut de Recerca Biomèdica de Lleida. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Institut de Recerca Biomèdica de Lleida · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,966
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Obesity, Morbid with a site in Spain — 11 open to participants now, 14 under way, 1 of them phase 3. Obesity, Morbid · Spain.

Planned enrollment
Largest of 13
6,966 · median 145
Started
2024
with 2 others
Observational
13 of 38
5 open now
Primary completion
2027-03
later than 5 of 13 live
Registered
30th of 38
by date

Among the 38 studies in Obesity, Morbid with a site in Spain, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, reaches primary completion later than 5 of the 13 other live ones, and was the 30th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

11 of the 38 studies in Obesity, Morbid with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Obesity, Morbid with a site in Spain, or all of them as a file.
02

Study summary

Obesity is a complex chronic disease, in which both genetic and environmental factors are involved, that shows a great heterogeneity in the response to different weight loss programs. Identifying patients as responder or no responder to the different obesity treatment options is a concept of great interest, both due to the high prevalence of obesity and its high consumption of resources. More than 500,000 surgeries are performed every year around the world, of which approximately 30% will present unsatisfactory results.

The general objective is to carry out a multi-omics approach for the discovery and validation of markers of weight response to bariatric surgery (BS) in a large sample of people with severe obesity (n=6,966 men and women who underwent sleeve gastrectomy or gastric bypass, including an additional external validation set). Thus, the investigators want to know the integrated contribution of several genomic markers (Genome Wide Association study, GWAs), new clinical and analytical variables (human exposome concept) and gender perspective to the prediction of response to the intervention at 12 month and its long-term longitudinal maintenance (3 years). The investigators intend, therefore, to provide new evidence to advance towards precision medicine. The investigators will focus our attention also on identifying those patients who, after being classified at the weight loss nadir as responders experienced weight regain.

03

Conditions studied

  • Bariatric Surgery Candidate
  • Obesity, Morbid
  • Genetic Predisposition
  • Metabolic Syndrome
  • Weight Loss
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This multicenter retrospective study will be aimed at 6,966 obese patients undergoing BS, whose surgical technique (sleeve gastrectomy vs gastric bypass) has been performed at least 3 years before, evaluating the best combination of genetic and exposomal characteristics (clinical and analytical) that will predict which patients will be responders and non-responders in terms of weight loss.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women between the ages of 18 and 65 at the time of surgery
  • SG or RYBP as bariatric procedure.
  • With a ≥35.0 kg/m2 with one or more comorbidities or a BMI>40.0 kg/m2 at the time of surgery.
  • Provision of an form signed and personally dated by the patient.
  • With available baseline data (anthropometric, analytical, surgical procedure, pharmacological therapies, and obesity-related comorbidities).

Exclusion criteria

Exclusion Criteria:

  • Any previous gastrointestinal surgery
  • Treatment with any approved antiobesity drug in Spain (orlistat, liraglutide 3.0 mg and/or naltrexone/bupropion extended release) or systemic for more than 4 consecutive weeks during the 3 years following BS
  • End stage kidney disease ( \<15 ml/min/1.73m2) or liver cirrhosis at baseline
  • Patients who developed any major medical conditions that limits the practice of a healthy life within normal limits (advanced cardiovascular disease or heart failure, stroke with neurological sequelae, chronic pulmonary obstructive disease with dyspnea at minimal exertion, severe joint pathology, end stage renal failure, or active cancer)
  • Known type 1 diabetes or LADA diabetes
  • Women who become pregnant during the follow-up period
  • Current drug or alcohol abuse
  • Uncontrolled psychiatric illness or eating disorders developed during the follow-up period.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,966 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Lleida

    Saliva sample collection and questionnaire

  • Barcelona

    Saliva sample collection and questionnaire

  • Madrid

    Saliva sample collection and questionnaire

  • Málaga

    Saliva sample collection and questionnaire

  • Santiago de Compostela

    Saliva sample collection and questionnaire

  • Pamplona

    Saliva sample collection and questionnaire

  • León

    Saliva sample collection and questionnaire

  • A Coruña

    Saliva sample collection and questionnaire

  • Mallorca

    Saliva sample collection and questionnaire

  • Tenerife

    Saliva sample collection and questionnaire

  • Las Palmas

    Saliva sample collection and questionnaire

06

What researchers measure

Primary outcomes

  1. Genomic markers that can predict the weight change response to bariatric surgery

    Percentage of initial weight change

    Time frame: 3 years

Secondary outcomes

  1. Genomic markers that can predict comorbidities response to bariatric surgery

    Type 2 diabetes mellitus, sleep apnea, fatty liver

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • IRBLleida
    Lleida, Leida 25198, Spain
    Recruiting
08

References and documents

Publications

  • Breton I, de Hollanda A, Vilarrasa N, Rubio Herrera MA, Lecube A, Salvador J, Garcia-Luna PP, Tinahones FJ, Sanchez Santos R, Gomez Huelgas R, Carretero Gomez J, Moize V, Polo Garcia J, Tranche Iparraguirre S, Fernandez-Pro Ledesma A, Escalada J; representing SEEN, SEEDO, SECO, SEMI, SEDYN, SEMERGEN, semFYC and SEMG. Obesity and COVID-19. A necessary position statement. Endocrinol Diabetes Nutr (Engl Ed). 2021 Oct;68(8):573-576. doi: 10.1016/j.endien.2021.02.004. Epub 2021 Nov 18. No abstract available. PubMed 34872641 ↗
  • Ballesteros Pomar MD, Vilarrasa Garcia N, Rubio Herrera MA, Barahona MJ, Bueno M, Caixas A, Calanas Continente A, Ciudin A, Cordido F, de Hollanda A, Diaz MJ, Flores L, Garcia Luna PP, Garcia Perez-Sevillano F, Goday A, Lecube A, Lopez Gomez JJ, Minambres I, Morales Gorria MJ, Morinigo R, Nicolau J, Pellitero S, Salvador J, Valdes S, Breton Lesmes I. The SEEN comprehensive clinical survey of adult obesity: Executive summary. Endocrinol Diabetes Nutr (Engl Ed). 2021 Feb;68(2):130-136. doi: 10.1016/j.endinu.2020.05.003. Epub 2020 Sep 12. English, Spanish. PubMed 32933882 ↗
  • Beisani M, Sabench Pereferrer F, Vilallonga R, Gonzalez Lopez O, Molina Lopez A, Del Castillo Dejardin D, Garcia Ruiz de Gordejuela A, Fort Lopez-Barajas JM, Armengol Carrasco M; Members of the Obesity Section of the Spanish Surgical Association Collaborative Group. Seeking an Initial-Weight-Independent Metric in a Mediterranean Cohort of Gastric Bypass Patients: the %AWL Revisited. Obes Surg. 2021 Apr;31(4):1524-1532. doi: 10.1007/s11695-020-05154-3. Epub 2021 Jan 4. PubMed 33398625 ↗
  • Caixas A, Villaro M, Arraiza C, Montalva JC, Lecube A, Fernandez-Garcia JM, Corio R, Bellido D, Llisterri JL, Tinahones FJ. SEEDO-SEMERGEN consensus document on continuous care of obesity between Primary Care and Specialist Hospital Units 2019. Med Clin (Barc). 2020 Sep 25;155(6):267.e1-267.e11. doi: 10.1016/j.medcli.2019.10.014. Epub 2020 Feb 17. English, Spanish. PubMed 32081378 ↗
  • Martinez-Ortega AJ, Olveira G, Pereira-Cunill JL, Arraiza-Irigoyen C, Garcia-Almeida JM, Irles Rocamora JA, Molina-Puerta MJ, Molina Soria JB, Rabat-Restrepo JM, Rebollo-Perez MI, Serrano-Aguayo MP, Tenorio-Jimenez C, Vilches-Lopez FJ, Garcia-Luna PP. Recommendations Based on Evidence by the Andalusian Group for Nutrition Reflection and Investigation (GARIN) for the Pre- and Postoperative Management of Patients Undergoing Obesity Surgery. Nutrients. 2020 Jul 6;12(7):2002. doi: 10.3390/nu12072002. PubMed 32640531 ↗
  • Vilallonga R, Pereira-Cunill JL, Morales-Conde S, Alarcon I, Breton I, Dominguez-Adame E, Ferrer JV, Ruiz-de-Gordejuela AG, Goday A, Lecube A, Garcia-Almenta EM, Rubio MA, Tinahones FJ, Garcia-Luna PP. A Spanish Society joint SECO and SEEDO approach to the Post-operative management of the patients undergoing surgery for obesity. Obes Surg. 2019 Dec;29(12):3842-3853. doi: 10.1007/s11695-019-04043-8. PubMed 31342249 ↗
  • Lecube A, Monereo S, Rubio MA, Martinez-de-Icaya P, Marti A, Salvador J, Masmiquel L, Goday A, Bellido D, Lurbe E, Garcia-Almeida JM, Tinahones FJ, Garcia-Luna PP, Palacio E, Gargallo M, Breton I, Morales-Conde S, Caixas A, Menendez E, Puig-Domingo M, Casanueva FF. Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity. Endocrinol Diabetes Nutr. 2017 Mar;64 Suppl 1:15-22. doi: 10.1016/j.endonu.2016.07.002. Epub 2016 Aug 16. No abstract available. English, Spanish. PubMed 27543006 ↗
  • Yarnoz-Esquiroz P, Olazaran L, Aguas-Ayesa M, Perdomo CM, Garcia-Goni M, Silva C, Fernandez-Formoso JA, Escalada J, Montecucco F, Portincasa P, Fruhbeck G. 'Obesities': Position statement on a complex disease entity with multifaceted drivers. Eur J Clin Invest. 2022 Jul;52(7):e13811. doi: 10.1111/eci.13811. Epub 2022 May 12. PubMed 35514242 ↗
  • Linares-Pineda TM, Boughanem H, Gutierrez-Repiso C, Macias-Gonzalez M, Andres-Leon E, Rojo-Martinez G, Valdes S, Tinahones FJ, Morcillo S. Epigenetic changes in the metabolically healthy obese: A case-control versus a prospective study. Eur J Clin Invest. 2022 Aug;52(8):e13783. doi: 10.1111/eci.13783. Epub 2022 Apr 11. No abstract available. PubMed 35342930 ↗
  • Martinez MC, Meli EF, Candia FP, Filippi F, Vilallonga R, Cordero E, Hernandez I, Eguinoa AZ, Burgos R, Vila A, Simo R, Ciudin A. The Impact of Bariatric Surgery on the Muscle Mass in Patients with Obesity: 2-Year Follow-up. Obes Surg. 2022 Mar;32(3):625-633. doi: 10.1007/s11695-021-05815-x. Epub 2021 Nov 30. PubMed 34846686 ↗
  • Lecube A, Ciudin A. A long and stony road to the correct treatment of obesity. Med Clin (Barc). 2021 Aug 27;157(4):176-177. doi: 10.1016/j.medcli.2021.06.004. Epub 2021 Jul 10. No abstract available. English, Spanish. PubMed 34253348 ↗
  • Torrego-Ellacuria M, Barabash A, Larrad-Sainz A, Hernandez-Nunez GM, Matia-Martin P, Perez-Ferre N, Marcuello C, Sanchez-Pernaute A, Torres AJ, Calle-Pascual AL, Rubio MA. Weight Regain Outcomes After Bariatric Surgery in the Long-term Follow-up: Role of Preoperative Factors. Obes Surg. 2021 Sep;31(9):3947-3955. doi: 10.1007/s11695-021-05497-5. Epub 2021 Jun 19. PubMed 34146246 ↗
  • Gutierrez-Repiso C, Linares-Pineda TM, Gonzalez-Jimenez A, Aguilar-Lineros F, Valdes S, Soriguer F, Rojo-Martinez G, Tinahones FJ, Morcillo S. Epigenetic Biomarkers of Transition from Metabolically Healthy Obesity to Metabolically Unhealthy Obesity Phenotype: A Prospective Study. Int J Mol Sci. 2021 Sep 27;22(19):10417. doi: 10.3390/ijms221910417. PubMed 34638758 ↗
  • Ciudin A, Fidilio E, Gutierrez-Carrasquilla L, Caixas A, Vilarrasa N, Pellitero S, Simo-Servat A, Vilallonga R, Ruiz A, de la Fuente M, Luna A, Sanchez E, Rigla M, Hernandez C, Salas E, Simo R, Lecube A. A Clinical-Genetic Score for Predicting Weight Loss after Bariatric Surgery: The OBEGEN Study. J Pers Med. 2021 Oct 17;11(10):1040. doi: 10.3390/jpm11101040. PubMed 34683180 ↗
  • Nicolau J, Dotres K, Ayala L, Rodriguez I, Pascual S, Sanchis P, Bonet A, Tamayo MI, Arteaga M, Fortuny R, Cifuentes A, Masmiquel L. Long-Term Prevalence of Food Addiction Among Bariatric Surgery Patients: Influence on Metabolic and Psychological Outcomes. Metab Syndr Relat Disord. 2021 Apr;19(3):152-158. doi: 10.1089/met.2020.0079. Epub 2021 Feb 18. PubMed 33601956 ↗
  • Fidilio E, Comas M, Giribes M, Cardenas G, Vilallonga R, Palma F, Pelaez RB, Simo R, Ciudin A. Evaluation of Resting Energy Expenditure in Subjects with Severe Obesity and Its Evolution After Bariatric Surgery. Obes Surg. 2021 Oct;31(10):4347-4355. doi: 10.1007/s11695-021-05578-5. Epub 2021 Aug 3. PubMed 34345955 ↗
  • Cornejo-Pareja I, Molina-Vega M, Gomez-Perez AM, Damas-Fuentes M, Tinahones FJ. Factors Related to Weight Loss Maintenance in the Medium-Long Term after Bariatric Surgery: A Review. J Clin Med. 2021 Apr 16;10(8):1739. doi: 10.3390/jcm10081739. PubMed 33923789 ↗
  • Alvarez-Bermudez MD, Martin-Reyes F, Ocana-Wilhelmi L, Moreno-Ruiz FJ, Torres JA, Fernandez-Garcia D, Valdes S, Moreno-Morales N, Garcia-Fuentes E, Tinahones FJ, Garrido-Sanchez L. Variables Associated with Short-Term Weight Loss in a Cohort of Patients with Morbid Obesity According to Age and Three Types of Bariatric Surgery. J Clin Med. 2020 Nov 2;9(11):3537. doi: 10.3390/jcm9113537. PubMed 33147793 ↗
  • Hollanda A, Lecube A, Rubio MA, Sanchez E, Vilarrasa N, Oliva JG, Fernandez-Soto ML, Salas-Salvado J, Ballesteros-Pomar MD, Ciudin A, Torres F, Vidal C, Morales MJ, Valdes S, Pellitero S, Minambres I, Masmiquel L, Goday A, Suarez L, Flores L, Bueno M, Caixas A, Breton I, Camara R, Olbeyra R, Penso R, Jose de la Cruz M, Simo-Servat A, Pereyra-Garcia FM, Lopez-Mezquita ET, Gils A, Fidilio E, Bandres O, Martinez A, Abuin J, Marques-Pamies M, Tuneu L, Arteaga M, Castaner O, Goni F, Arrizabalaga C, Botana MA, Calanas A, Rebollo A. New Metrics to Assess Type 2 Diabetes After Bariatric Surgery: The "Time-Within-Remission Range". J Clin Med. 2020 Apr 9;9(4):1070. doi: 10.3390/jcm9041070. PubMed 32283783 ↗
  • Palau-Rodriguez M, Garcia-Aloy M, Minarro A, Bernal-Lopez MR, Brunius C, Gomez-Huelgas R, Landberg R, Tinahones FJ, Andres-Lacueva C. Effects of a long-term lifestyle intervention on metabolically healthy women with obesity: Metabolite profiles according to weight loss response. Clin Nutr. 2020 Jan;39(1):215-224. doi: 10.1016/j.clnu.2019.01.018. Epub 2019 Feb 16. PubMed 30862367 ↗
  • Serrano JCE, Baena-Fustegueras JA, Martin-Gari M, Rassendren H, Cassanye A, Naudi A, Lopez-Cano C, Sanchez E, de la Fuente-Juarez MC, Herrerias Gonzalez F, Olsina Kissler JJ, Lecube A, Portero-Otin M. Adipose Tissue Protein Glycoxidation is Associated with Weight-Loss Potential. Obesity (Silver Spring). 2019 Jul;27(7):1133-1140. doi: 10.1002/oby.22501. Epub 2019 May 21. PubMed 31112015 ↗
  • Ciudin A, Fidilio E, Ortiz A, Pich S, Salas E, Mesa J, Hernandez C, Simo-Servat O, Lecube A, Simo R. Genetic Testing to Predict Weight Loss and Diabetes Remission and Long-Term Sustainability after Bariatric Surgery: A Pilot Study. J Clin Med. 2019 Jul 3;8(7):964. doi: 10.3390/jcm8070964. PubMed 31277226 ↗
  • Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Metabolic and Endocrine Consequences of Bariatric Surgery. Front Endocrinol (Lausanne). 2019 Sep 19;10:626. doi: 10.3389/fendo.2019.00626. eCollection 2019. PubMed 31608009 ↗
  • Arteaga-Gonzalez IJ, Martin-Malagon AI, Ruiz de Adana JC, de la Cruz Vigo F, Torres-Garcia AJ, Carrillo-Pallares AC. Bariatric Surgery Waiting Lists in Spain. Obes Surg. 2018 Dec;28(12):3992-3996. doi: 10.1007/s11695-018-3453-z. PubMed 30121853 ↗
  • Nicolau J, Simo R, Sanchis P, Ayala L, Fortuny R, Rivera R, Masmiquel L. Effects of depressive symptoms on clinical outcomes, inflammatory markers and quality of life after a significant weight loss in a bariatric surgery sample. Nutr Hosp. 2017 Feb 1;34(1):81-87. doi: 10.20960/nh.979. PubMed 28244776 ↗
  • Morcillo S, Martin-Nunez GM, Garcia-Serrano S, Gutierrez-Repiso C, Rodriguez-Pacheco F, Valdes S, Gonzalo M, Rojo-Martinez G, Moreno-Ruiz FJ, Rodriguez-Canete A, Tinahones F, Garcia-Fuentes E. Changes in SCD gene DNA methylation after bariatric surgery in morbidly obese patients are associated with free fatty acids. Sci Rep. 2017 Apr 10;7:46292. doi: 10.1038/srep46292. PubMed 28393901 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Mar 2027, 36 months later.

Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 36 months is below that.

Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2024
First posted
Jan 26, 2024
StartEst.
Mar 15, 2024
Primary completionEst.
Mar 15, 2027
CompletionEst.
Nov 29, 2028
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06226194
Lead sponsor
Institut de Recerca Biomèdica de Lleida
Collaborators
ISCIII
Responsible party
Albert Lecube Torello (Head of Endocrinology Department Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica de Lleida) — Principal investigator
First posted
Jan 26, 2024
Start date
Mar 15, 2024 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
Nov 29, 2028 (estimated)
Last update
Mar 6, 2024

Study contacts

Albert Lecube Torelló, PhD
Contact
alecube@gmail.com
0034973705183
Eva López
Contact
elopez@irblleida.cat
0034973706636
Albert Lecube Torelló, PhD
study chair · Institut de Recerca Biomèdica de Lleida
Rafael Simo, PhD
study director · Vall d'Hebron Research Institute
Miguel Angel Rubio, PhD
principal investigator · Instituto de Investigación Sanitaria Hospital Clínico San Carlos
Francisco Tinahones, PhD
principal investigator · Instituto de Investigación Biomédica de Málaga
Javier Escalada, PhD
principal investigator · Clínica Universidad de Navarra Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion